Drug profile · INN
granisetron
SANCUSO
granisetron (SANCUSO) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Heron Therapeutics. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — granisetron
- US status
- approved
- Class
- Alimentary tract and metabolism (A04)
- Route
- SUBCUTANEOUS
- Patents
- 3
- Programs
- 5
- Data quality
- 0.89
Quick answer
granisetron (SANCUSO) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Heron Therapeutics. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 3a (5-HT3a) receptor antagonist
Primary target: 5-hydroxytryptamine receptor 3A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 10357570
Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
granted -
US 9913910
Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
granted -
US 8715710
Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
granted
Frequently asked questions
What is granisetron?
granisetron (SANCUSO) is a serotonin 3a (5-ht3a) receptor antagonist. Associated with Heron Therapeutics. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for granisetron?
SANCUSO is a marketed brand name for granisetron. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of granisetron?
granisetron has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.